1
|
Bellinato F, Gisondi P, Dattola A, Richetta AG, Costanzo A, Valenti M, De Simone C, Marzano AV, Zussino M, Pezzolo E, Nacca M, Pellacani G, Girolomoni G. Spesolimab in patients with flare of generalized pustular psoriasis: A multicentre case-series. J Eur Acad Dermatol Venereol 2024; 38:e437-e439. [PMID: 38084869 DOI: 10.1111/jdv.19678] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Accepted: 11/17/2023] [Indexed: 04/26/2024]
Affiliation(s)
- F Bellinato
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| | - P Gisondi
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| | - A Dattola
- Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
| | - A G Richetta
- Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
| | - A Costanzo
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy
- Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| | - M Valenti
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy
- Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| | - C De Simone
- Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
| | - A V Marzano
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
| | - M Zussino
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
| | - E Pezzolo
- Dermatology Unit, Ospedale San Bortolo, Vicenza, Italy
| | - M Nacca
- A.O.R.N. Sant'Anna e San Sebastiano Caserta, Caserta, Italy
| | - G Pellacani
- Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
| | - G Girolomoni
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| |
Collapse
|
2
|
Gargiulo L, Ibba L, Fiorillo G, Valenti M, Sierzputowska P, Costanzo A, Narcisi A. Pregnancy outcome of a patient treated with upadacitinib for severe atopic dermatitis. J Eur Acad Dermatol Venereol 2024; 38:e252-e253. [PMID: 37795665 DOI: 10.1111/jdv.19557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Accepted: 09/27/2023] [Indexed: 10/06/2023]
Affiliation(s)
- L Gargiulo
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | - L Ibba
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | - G Fiorillo
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | - M Valenti
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | | | - A Costanzo
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | - A Narcisi
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| |
Collapse
|
3
|
Orsini D, Frascione P, Assorgi C, Pacifico A, Sperduti I, Gargiulo L, Ibba L, Valenti M, Costanzo A, Narcisi A. Risankizumab for the treatment of genital psoriasis: A 1-year, real-world experience. J Eur Acad Dermatol Venereol 2024; 38:e256-e258. [PMID: 37795669 DOI: 10.1111/jdv.19562] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Accepted: 09/27/2023] [Indexed: 10/06/2023]
Affiliation(s)
- D Orsini
- Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy
| | - P Frascione
- Dermatology Oncology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy
| | - C Assorgi
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - A Pacifico
- Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy
| | - I Sperduti
- Biostatistical Unit, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy
| | - L Gargiulo
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy
- Department of Biomedical Sciences, Humanitas University, Italy
| | - L Ibba
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy
- Department of Biomedical Sciences, Humanitas University, Italy
| | - M Valenti
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy
- Department of Biomedical Sciences, Humanitas University, Italy
| | - A Costanzo
- Biostatistical Unit, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy
| | - A Narcisi
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy
| |
Collapse
|
4
|
Hedayat S, Cascione L, Cunningham D, Schirripa M, Lampis A, Hahne JC, Tunariu N, Hong SP, Marchetti S, Khan K, Fontana E, Angerilli V, Delrieux M, Nava Rodrigues D, Procaccio L, Rao S, Watkins D, Starling N, Chau I, Braconi C, Fotiadis N, Begum R, Guppy N, Howell L, Valenti M, Cribbes S, Kolozsvari B, Kirkin V, Lonardi S, Ghidini M, Passalacqua R, Elghadi R, Magnani L, Pinato DJ, Di Maggio F, Ghelardi F, Sottotetti E, Vetere G, Ciraci P, Vlachogiannis G, Pietrantonio F, Cremolini C, Cortellini A, Loupakis F, Fassan M, Valeri N. Circulating microRNA analysis in a prospective co-clinical trial identifies MIR652-3p as a response biomarker and driver of regorafenib resistance mechanisms in colorectal cancer. Clin Cancer Res 2024:734699. [PMID: 38376926 DOI: 10.1158/1078-0432.ccr-23-2748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 02/15/2024] [Accepted: 02/16/2024] [Indexed: 02/21/2024]
Abstract
BACKGROUND The multi-kinase inhibitor regorafenib has demonstrated efficacy in chemo-refractory metastatic colorectal cancer (mCRC) patients. However, lack of predictive biomarkers and concerns over significant toxicities hamper the use of regorafenib in clinical practice. METHODS Serial liquid biopsies were obtained at baseline and monthly until disease progression in chemo-refractory mCRC patients treated with regorafenib in a phase II clinical trial (PROSPECT-R n=40; NCT03010722) and in a multicentric validation cohort (n=241). Tissue biopsies collected at baseline, after 2 months and at progression in the PROSPECT-R trial were used to establish Patient-Derived Organoids (PDOs) and for molecular analyses. MicroRNA profiling was performed on baseline bloods using the NanoString nCounter platform and results were validated by digital droplet PCR and/or In Situ Hybridization in paired liquid and tissue biopsies. PDOs co-cultures and PDO-xenotransplants were generated for functional analyses. RESULTS Large-scale microRNA expression analysis in longitudinal matched liquid and tissue biopsies from the PROSPECT-R trial identified MIR652-3p as a biomarker of clinical benefit to regorafenib. These findings were confirmed in an independent validation cohort and in a "control" group of 100 patients treated with lonsurf. Using ex vivo co-culture assays paired with single-cell RNA-sequencing of PDO established pre- and post-treatment, we modelled regorafenib response observed in vivo and in patients, and showed that MIR652-3p controls resistance to regorafenib by impairing regorafenib-induced lethal autophagy and by orchestrating the switch from neo-angiogenesis to vessel co-option. CONCLUSIONS Our results identify MIR652-3p as potential biomarker and as a driver of cell and non-cell autonomous mechanisms of resistance to regorafenib.
Collapse
Affiliation(s)
| | - Luciano Cascione
- IOR - Institute of Oncology Research, Bellinzona, Ticino, Switzerland
| | | | - Marta Schirripa
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States
| | - Andrea Lampis
- Institute of Cancer Research, Sutton, United Kingdom
| | - Jens C Hahne
- Institute of Cancer Research, Sutton, United Kingdom
| | | | - Sung Pil Hong
- Yonsei University College of Medicine, Seoul, Korea (South), Republic of
| | | | - Khurum Khan
- Institute of Cancer Research, Sutton, United Kingdom
| | - Elisa Fontana
- Sarah Cannon Research Institute, London, London, United Kingdom
| | | | - Mia Delrieux
- Institute of Cancer Research, Sutton, United Kingdom
| | | | | | - Sheela Rao
- Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
| | | | | | - Ian Chau
- Royal Marsden Hospital, Sutton, Surrey, United Kingdom
| | | | | | - Ruwaida Begum
- Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom
| | - Naomi Guppy
- Institute of Cancer Research, London, United Kingdom
| | - Louise Howell
- Institute of Cancer Research, Sutton, Surrey, United Kingdom
| | | | | | | | | | - Sara Lonardi
- Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | | | | | | | - Luca Magnani
- Institute of Cancer Research, London, United Kingdom
| | | | | | | | | | | | - Paolo Ciraci
- Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | | | | | | | | | | | | | - Nicola Valeri
- Institute of Cancer Research, Sutton, London, United Kingdom
| |
Collapse
|
5
|
Gargiulo L, Ibba L, Piscazzi F, Alfano A, Cascio Ingurgio R, Valenti M, Costanzo A, Narcisi A. Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: A 52-week retrospective study. J Eur Acad Dermatol Venereol 2024; 38:e152-e154. [PMID: 37714196 DOI: 10.1111/jdv.19507] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 09/08/2023] [Indexed: 09/17/2023]
Affiliation(s)
- L Gargiulo
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| | - L Ibba
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| | - F Piscazzi
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| | - A Alfano
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| | - R Cascio Ingurgio
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| | - M Valenti
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| | - A Costanzo
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| | - A Narcisi
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
| |
Collapse
|
6
|
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Fabbrocini G, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Sampogna F, Travaglini M, Valenti M, Costanzo A, Narcisi A. A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol 2024; 38:e113-e116. [PMID: 37611277 DOI: 10.1111/jdv.19464] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Accepted: 08/18/2023] [Indexed: 08/25/2023]
Affiliation(s)
- L Gargiulo
- Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - L Ibba
- Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - P Malagoli
- Department of Dermatology, Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy
| | - F Amoruso
- Dermatology Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy
| | - G Argenziano
- Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy
| | - A Balato
- Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy
| | - F Bardazzi
- Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy
| | - M Burlando
- Department of Dermatology, Dipartimento di Scienze della Salute (DISSAL), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
| | - C G Carrera
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - G Damiani
- Department of Biomedical, Surgical, and Dental Sciences, University of Milan, Milan, Italy
- Clinical Dermatology, IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milan, Italy
| | - P Dapavo
- Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy
| | - V Dini
- Dermatology Unit, Department of Clinical and Experimental Medicine Ospedale Santa Chiara, Pisa, Italy
| | - G Fabbrocini
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - C Franchi
- Clinical Dermatology, IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milan, Italy
| | - F M Gaiani
- Department of Dermatology, Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy
| | - G Girolomoni
- Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy
| | - C Guarneri
- Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Unit of Dermatology, University of Messina, AOU Policlinico G. Martino, Messina, Italy
| | - C Lasagni
- Dermatological Clinic, Department of Specialized Medicine, University of Modena, Modena, Italy
| | - F Loconsole
- Department of Dermatology, University of Bari, Bari, Italy
| | - A V Marzano
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
| | - M Maurelli
- Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy
| | - M Megna
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - D Orsini
- UOC Clinical Dermatology - Dermatological Institute S. Gallicano, IRCCS, Rome, Italy
| | - F Sampogna
- Clinical Epidemiology Unit, Istituto Dermopatico dell'Immacolata (IDI) IRCCS, Rome, Italy
| | - M Travaglini
- U.O.S.D. Dermatologica - Centro per la Cura Della Psoriasi, Brindisi, Italy
| | - M Valenti
- Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - A Costanzo
- Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - A Narcisi
- Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy
| |
Collapse
|
7
|
Fiorillo G, Ibba L, Gargiulo L, Vignoli CA, Alfano A, Cortese A, Toso F, Orsini D, Iacovelli P, Frascione P, Narcisi A, Costanzo A, Valenti M. Effectiveness and safety of anti-IL-23 and anti-IL-17 biological therapies for psoriasis in elderly patients: Real-world experience from two Italian hospitals. J Eur Acad Dermatol Venereol 2023; 37:e1444-e1446. [PMID: 37458684 DOI: 10.1111/jdv.19355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Accepted: 07/12/2023] [Indexed: 07/25/2023]
Affiliation(s)
- G Fiorillo
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | - L Ibba
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | - L Gargiulo
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | - C A Vignoli
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | - A Alfano
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | - A Cortese
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | - F Toso
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | - D Orsini
- Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy
| | - P Iacovelli
- Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy
| | - P Frascione
- Dermatology Oncology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy
| | - A Narcisi
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | - A Costanzo
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| | - M Valenti
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
| |
Collapse
|
8
|
Harnden A, Davis OA, Box GM, Hayes A, Johnson LD, Henley AT, de Haven Brandon AK, Valenti M, Cheung KMJ, Brennan A, Huckvale R, Pierrat OA, Talbot R, Bright MD, Akpinar HA, Miller DSJ, Tarantino D, Gowan S, de Klerk S, McAndrew PC, Le Bihan YV, Meniconi M, Burke R, Kirkin V, van Montfort RLM, Raynaud FI, Rossanese OW, Bellenie BR, Hoelder S. Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones. J Med Chem 2023; 66:5892-5906. [PMID: 37026591 PMCID: PMC10150366 DOI: 10.1021/acs.jmedchem.3c00155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Indexed: 04/08/2023]
Abstract
B-cell lymphoma 6 (BCL6) is a transcriptional repressor and oncogenic driver of diffuse large B-cell lymphoma (DLBCL). Here, we report the optimization of our previously reported tricyclic quinolinone series for the inhibition of BCL6. We sought to improve the cellular potency and in vivo exposure of the non-degrading isomer, CCT373567, of our recently published degrader, CCT373566. The major limitation of our inhibitors was their high topological polar surface areas (TPSA), leading to increased efflux ratios. Reducing the molecular weight allowed us to remove polarity and decrease TPSA without considerably reducing solubility. Careful optimization of these properties, as guided by pharmacokinetic studies, led to the discovery of CCT374705, a potent inhibitor of BCL6 with a good in vivo profile. Modest in vivo efficacy was achieved in a lymphoma xenograft mouse model after oral dosing.
Collapse
Affiliation(s)
- Alice
C. Harnden
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Owen A. Davis
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Gary M. Box
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Angela Hayes
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Louise D. Johnson
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Alan T. Henley
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Alexis K. de Haven Brandon
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Melanie Valenti
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Kwai-Ming J. Cheung
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Alfie Brennan
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Rosemary Huckvale
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Olivier A. Pierrat
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Rachel Talbot
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Michael D. Bright
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Hafize Aysin Akpinar
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Daniel S. J. Miller
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Dalia Tarantino
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Sharon Gowan
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Selby de Klerk
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Peter Craig McAndrew
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Yann-Vaï Le Bihan
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Mirco Meniconi
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Rosemary Burke
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Vladimir Kirkin
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Rob L. M. van Montfort
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Florence I. Raynaud
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Olivia W. Rossanese
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Benjamin R. Bellenie
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| | - Swen Hoelder
- Centre
for Cancer Drug Discovery and Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K.
| |
Collapse
|
9
|
Valenti M, Pino MC, Le Donne I, Vagnetti R, Tiberti S, Attanasio M, Mazza M. Adaptive response of Italian young adults with autism to the COVID-19 pandemic: A longitudinal study. Res Dev Disabil 2022; 131:104333. [PMID: 36162352 PMCID: PMC9464572 DOI: 10.1016/j.ridd.2022.104333] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Revised: 07/18/2022] [Accepted: 09/09/2022] [Indexed: 06/16/2023]
Abstract
The COVID-19 pandemic has represented a hazardous situation for individuals with Autism Spectrum Disorder (ASD) and their families. The difficulties, following the COVID-19-derived lockdown, have involved working from home or loss of employment, and the demands of looking after their children without the daily support of specialists. The aim of this study was to evaluate the adaptive behaviour of young adult participants with ASD after the enforcement of lockdown measures in March 2020 in a specialised centre in central Italy, by administering the Italian form of the Vineland Adaptive Behaviour Scales Second Edition (VABS-II), at baseline as well as 6 months and 1 year after the lockdown. Participants with ASD who were not able to access their normal, in-person care - they were only followed at a distance (i.e. telehealth) - declined dramatically in their adaptive behaviour during the first months after the lockdown for some VABS-II dimensions such as the socialisation and daily living domains. The effects of the lockdown on adaptive behaviour remained after 1 year. Our results emphasise the need for immediate, continuous and personal support for people with ASD during and after the restrictions caused by the COVID-19 pandemic, in order to ensure at least partial recovery of adaptive functioning.
Collapse
Affiliation(s)
- M Valenti
- Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, Località Coppito, L'Aquila 67100, Italy; Reference Regional Centre for Autism, Abruzzo Region Health System, L'Aquila, Italy.
| | - M C Pino
- Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, Località Coppito, L'Aquila 67100, Italy.
| | - I Le Donne
- Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, Località Coppito, L'Aquila 67100, Italy; Reference Regional Centre for Autism, Abruzzo Region Health System, L'Aquila, Italy.
| | - R Vagnetti
- Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, Località Coppito, L'Aquila 67100, Italy.
| | - S Tiberti
- Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, Località Coppito, L'Aquila 67100, Italy.
| | - M Attanasio
- Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, Località Coppito, L'Aquila 67100, Italy; Reference Regional Centre for Autism, Abruzzo Region Health System, L'Aquila, Italy.
| | - M Mazza
- Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Via Vetoio, Località Coppito, L'Aquila 67100, Italy.
| |
Collapse
|
10
|
Silvestri M, Reduzzi C, Vismara M, Valenti M, Folli S, Cristofanilli M, Pruneri G, Di Cosimo S, Cappelletti V. 136P Paths of chromosomal instability and copy number alteration in circulating tumor cells of progressing early-stage breast cancer patients. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.09.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
11
|
Workman P, Clarke P, Te Poele R, Powers M, Box G, De Billy E, De Haven Brandon A, Hallsworth A, Hayes A, McCann H, Sharp S, Valenti M, Raynaud F, Eccles S, Cheeseman M, Jones K. Discovery and validation of biomarkers to support clinical development of NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00893-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Ruscitti P, Ursini F, Berardicurti O, Masedu F, Bozzalla Cassione E, Naldi S, DI Cola I, DI Muzio C, De Stefano L, DI Nino E, Sensini F, Navarini L, Vomero M, Bugatti S, Valenti M, Mariani E, Iagnocco A, Montecucco C, Giacomelli R, Cipriani P. OP0044 CYTOKINE PROFILE, HYPERFERRITINEMIA, AND MULTI-VISCERAL INVOLVEMENT CHARACTERISE MACROPHAGE ACTIVATION SYNDROME COMPLICATING ADULT ONSET STILL’S DISEASE. RESULTS FROM A MULTIDIMENSIONAL EVALUATION. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundAdult-onset Still’s disease (AOSD) is a rare multigenic autoinflammatory disease of unknown aetiology burdened by life-threatening, such as macrophage activation syndrome (MAS) [1]. Considering the poor outcome of MAS patients, previous works tried to assess predictive factors of its occurrence during AOSD [2-4]. However, an integrated evaluation of clinical features with biomolecules, more reflecting the pathogenic mechanisms of the disease and its complications, is still missing.ObjectivesTo multidimensionally characterise MAS complicating AOSD considering cytokine profile, inflammatory markers, and multi-visceral involvement of the disease. To perform a high-dimensional phenotypic analysis of circulating immune cells in AOSD patients with and without MAS. To assess interferon (IFN)-related pathways in AOSD synovial tissues by a bulky RNA sequencing.MethodsThe present evaluation was designed to multidimensionally compare AOSD patients with or without MAS, considering cytokine profile, inflammatory markers, and multi-visceral involvement of the disease. Clinical and biologic data were collected and compared in AOSD patients with and without MAS. Sera biomolecules were analysed by Luminex multiplexing technology. Mass cytometry (CyTOF) was used to characterise circulating immune cells. A bulky RNA sequencing was performed in AOSD synovial tissues.ResultsIn this study, 40 consecutive AOSD patients (47.7±15.0 years, 50.0% male gender) were assessed at the time of diagnosis before the administration of any immunosuppressive therapy. Out of those, 14 (35%) patients were complicated by MAS. Paralleling with increases of systemic score and ferritin, MAS patients were characterised by an increased concentration of IL-1α, IL-1β, IL-1Ra, IL-2Ra, IL-6, IL-10, IL-17A, IFN-γ, G-CSF, MCP-1, MIP-1α, SCF. Among these biomolecules, IL-1Ra, IFN-γ, MCP-1, and SCF were correlated with MAS.Combining the discriminatory ability of these data in identifying MAS, the best model was composed by systemic score, ferritin, IFN-γ, and IL-10. This model was characterised by AUC=0.99 (Standard error: 0.008; 95%CI: 0.976–1.000), sensitivity=100%, specificity=95.45%. By CyTOF analysis, AOSD patients, who were complicated or not with MAS were characterised by a significant increase of circulating “classical monocytes” (CD14+CD38+). MAS patients were characterised by a significant reduction of NK cells (CD45RA+CD56dim) than AOSD patients. Finally, the transcriptomic profile, by RNA-sequencing analysis, showed that 3477 among type I, II, and III IFN-related genes (IRGs) were significantly different in AOSD synovial tissues.ConclusionA multidimensional characterisation of AOSD patients was provided suggesting that IFN-γ, IL-10, ferritin, and systemic score discriminated MAS, thus identifying the occurrence of the cytokine storm syndrome. The inflammatory milieu of AOSD and MAS may be associated with a signature of circulating immune cells. Finally, our results about IRGs reinforced the role of IFN-γ in these patients.References[1]Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun. 2018;93:24-36.[2]Ruscitti P, et al. Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. J Rheumatol. 2018;45:864-872.[3]Di Benedetto P, et al. Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still’s disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. PLoS One. 2020;15:e0235326.[4]Wan L, et al. Total metabolic lesion volume of lymph nodes measured by 18F-FDG PET/CT: a new predictor of macrophage activation syndrome in adult-onset Still’s disease. Arthritis Res Ther. 2021;23:97.Disclosure of InterestsNone declared.
Collapse
|
13
|
Parisotto M, Morabito V, Ferretti S, Reversi L, Cesarini F, Valenti M. PO-1630 An analytic method for inhomogeneity correction of Gafchromic EBT3 films. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03594-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
La Rocca E, De Santis MC, Silvestri M, Ortolan E, Valenti M, Folli S, de Braud FG, Bianchi GV, Scaperrotta GP, Apolone G, Daidone MG, Cappelletti V, Pruneri G, Di Cosimo S. Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA. J Cancer Res Clin Oncol 2022; 148:1543-1550. [PMID: 35396978 PMCID: PMC9114063 DOI: 10.1007/s00432-022-03990-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Accepted: 03/20/2022] [Indexed: 11/28/2022]
Abstract
Purpose Physical examinations and annual mammography (minimal follow-up) are as effective as laboratory/imaging tests (intensive follow-up) in detecting breast cancer (BC) recurrence. This statement is now challenged by the availability of new diagnostic tools for asymptomatic cases. Herein, we analyzed current practices and circulating tumor DNA (ctDNA) in monitoring high-risk BC patients treated with curative intent in a comprehensive cancer center. Patients and methods Forty-two consecutive triple negative BC patients undergoing neoadjuvant therapy and surgery were prospectively enrolled. Data from plasma samples and surveillance procedures were analyzed to report the diagnostic pattern of relapsed cases, i.e., by symptoms, follow-up procedures and ctDNA. Results Besides minimal follow-up, 97% and 79% of patients had at least 1 non-recommended imaging and laboratory tests for surveillance purposes. During a median follow-up of 5.1(IQR, 4.1–5.9) years, 13 events occurred (1 contralateral BC, 1 loco-regional recurrence, 10 metastases, and 1 death). Five recurrent cases were diagnosed by intensive follow-up, 5 by symptoms, and 2 incidentally. ctDNA antedated disseminated disease in all evaluable cases excepted two with bone-only and single liver metastases. The mean time from ctDNA detection to suspicious findings at follow-up imaging was 3.81(SD, 2.68), and to definitive recurrence diagnosis 8(SD, 2.98) months. ctDNA was undetectable in the absence of disease and in two suspected cases not subsequently confirmed. Conclusions Some relapses are still symptomatic despite the extensive use of intensive follow-up. ctDNA is a specific test, sensitive enough to detect recurrence before other methods, suitable for clarifying equivocal imaging, and exploitable for salvage therapy in asymptomatic BC survivors. Supplementary Information The online version contains supplementary material available at 10.1007/s00432-022-03990-7.
Collapse
Affiliation(s)
- E La Rocca
- Breast Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,Radiation Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - M C De Santis
- Breast Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,Radiation Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - M Silvestri
- Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - E Ortolan
- Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - M Valenti
- Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - S Folli
- Breast Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,Breast Cancer Surgery, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - F G de Braud
- Breast Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,School of Medicine, University of Milan, Milan, Italy
| | - G V Bianchi
- Breast Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - G P Scaperrotta
- Breast Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,Radiology Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - G Apolone
- Scientific Directorate, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - M G Daidone
- Scientific Directorate, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - V Cappelletti
- Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - G Pruneri
- Breast Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,School of Medicine, University of Milan, Milan, Italy.,Department of Pathology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - S Di Cosimo
- Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
| |
Collapse
|
15
|
Chan M, Gevaert T, Kadoya N, Dorr J, Leung R, Alheet S, Toutaoui A, Farias R, Wong M, Skourou C, Valenti M, Farré I, Otero-Martínez C, O'Doherty D, Waldron J, Hanvey S, Grohmann M, Liu H. Multi-center planning study of radiosurgery for intracranial metastases through Automation (MC-PRIMA) by crowdsourcing prior web-based plan challenge study. Phys Med 2022; 95:73-82. [DOI: 10.1016/j.ejmp.2022.01.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Revised: 01/10/2022] [Accepted: 01/28/2022] [Indexed: 10/19/2022] Open
|
16
|
Milton CI, Selfe J, Aladowicz E, Man SYK, Bernauer C, Missiaglia E, Walters ZS, Gatz SA, Kelsey A, Generali M, Box G, Valenti M, de Haven‐Brandon A, Galiwango D, Hayes A, Clarke M, Izquierdo E, Gonzalez De Castro D, Raynaud FI, Kirkin V, Shipley JM. FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas. Mol Oncol 2022; 16:1272-1289. [PMID: 34850536 PMCID: PMC8936514 DOI: 10.1002/1878-0261.13145] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2021] [Revised: 09/30/2021] [Accepted: 11/29/2021] [Indexed: 11/09/2022] Open
Abstract
Rhabdomyosarcomas are aggressive pediatric soft-tissue sarcomas and include high-risk PAX3-FOXO1 fusion-gene-positive cases. Fibroblast growth factor receptor 4 (FGFR4) is known to contribute to rhabdomyosarcoma progression; here, we sought to investigate the involvement and potential for therapeutic targeting of other FGFRs in this disease. Cell-based screening of FGFR inhibitors with potential for clinical repurposing (NVP-BGJ398, nintedanib, dovitinib, and ponatinib) revealed greater sensitivity of fusion-gene-positive versus fusion-gene-negative rhabdomyosarcoma cell lines and was shown to be correlated with high expression of FGFR2 and its specific ligand, FGF7. Furthermore, patient samples exhibit higher mRNA levels of FGFR2 and FGF7 in fusion-gene-positive versus fusion-gene-negative rhabdomyosarcomas. Sustained intracellular mitogen-activated protein kinase (MAPK) activity and FGF7 secretion into culture media during serum starvation of PAX3-FOXO1 rhabdomyosarcoma cells together with decreased cell viability after genetic silencing of FGFR2 or FGF7 was in keeping with a novel FGF7-FGFR2 autocrine loop. FGFR inhibition with NVP-BGJ398 reduced viability and was synergistic with SN38, the active metabolite of irinotecan. In vivo, NVP-BGJ398 abrogated xenograft growth and warrants further investigation in combination with irinotecan as a therapeutic strategy for fusion-gene-positive rhabdomyosarcomas.
Collapse
Affiliation(s)
- Christopher I. Milton
- Sarcoma Molecular Pathology TeamDivisions of Molecular Pathology and Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
- Present address:
Signal Transduction and Molecular Pharmacology TeamCancer Research UK Cancer Therapeutics UnitThe Institute of Cancer ResearchSuttonUK
| | - Joanna Selfe
- Sarcoma Molecular Pathology TeamDivisions of Molecular Pathology and Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
| | - Ewa Aladowicz
- Sarcoma Molecular Pathology TeamDivisions of Molecular Pathology and Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
| | - Stella Y. K. Man
- Sarcoma Molecular Pathology TeamDivisions of Molecular Pathology and Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
| | - Carolina Bernauer
- Sarcoma Molecular Pathology TeamDivisions of Molecular Pathology and Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
| | - Edoardo Missiaglia
- Sarcoma Molecular Pathology TeamDivisions of Molecular Pathology and Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
- Present address:
Department of Molecular PathologyCentre Hospitalier Universitaire VaudoisLausanneSwitzerland
| | - Zoë S. Walters
- Sarcoma Molecular Pathology TeamDivisions of Molecular Pathology and Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
- Present address:
Translational Epigenomics TeamHuman Development and HealthFaculty of MedicineSouthampton General HospitalUK
| | - Susanne A. Gatz
- Sarcoma Molecular Pathology TeamDivisions of Molecular Pathology and Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
- Present address:
Institute of Cancer and Genomic SciencesUniversity of BirminghamUK
| | - Anna Kelsey
- Department of Paediatric HistopathologyManchester University NHS Foundation TrustRoyal Manchester Children’s HospitalUK
| | - Melanie Generali
- Sarcoma Molecular Pathology TeamDivisions of Molecular Pathology and Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
- Present address:
Center for Therapy Development and Good Manufacturing PracticeInstitute for Regenerative Medicine (IREM)University of ZurichSwitzerland
| | - Gary Box
- Cancer Pharmacology and Stress Response TeamDivision of Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
| | - Melanie Valenti
- Cancer Pharmacology and Stress Response TeamDivision of Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
| | - Alexis de Haven‐Brandon
- Cancer Pharmacology and Stress Response TeamDivision of Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
| | - David Galiwango
- Drug Metabolism and Pharmacokinetics TeamDivision of Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
| | - Angela Hayes
- Drug Metabolism and Pharmacokinetics TeamDivision of Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
| | - Matthew Clarke
- Glioma TeamDivision of Molecular PathologyThe Institute of Cancer ResearchLondonUK
| | - Elisa Izquierdo
- Glioma TeamDivision of Molecular PathologyThe Institute of Cancer ResearchLondonUK
| | - David Gonzalez De Castro
- Molecular HaematologyDivision of Molecular PathologyThe Institute of Cancer ResearchLondonUK
- Present address:
School of MedicineDentistry and Biomedical sciencesQueens University BelfastUK
| | - Florence I. Raynaud
- Drug Metabolism and Pharmacokinetics TeamDivision of Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
| | - Vladimir Kirkin
- Cancer Pharmacology and Stress Response TeamDivision of Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
| | - Janet M. Shipley
- Sarcoma Molecular Pathology TeamDivisions of Molecular Pathology and Cancer TherapeuticsThe Institute of Cancer ResearchLondonUK
| |
Collapse
|
17
|
Pavia G, Gargiulo L, Spinelli F, Avagliano J, Valenti M, Borroni RG, Costanzo A, Narcisi A. Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID‐19 vaccine, successfully treated with risankizumab. J Eur Acad Dermatol Venereol 2022; 36:e502-e505. [PMID: 35224780 PMCID: PMC9114914 DOI: 10.1111/jdv.18032] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 01/21/2022] [Accepted: 02/21/2022] [Indexed: 11/26/2022]
Affiliation(s)
- G. Pavia
- Department of Biomedical Sciences Humanitas University Pieve Emanuele MI USA
- Dermatology Unit IRCCS Humanitas Research Hospital Rozzano MI) USA
| | - L. Gargiulo
- Department of Biomedical Sciences Humanitas University Pieve Emanuele MI USA
- Dermatology Unit IRCCS Humanitas Research Hospital Rozzano MI) USA
| | - F. Spinelli
- Dermatology Unit IRCCS Humanitas Research Hospital Rozzano MI) USA
| | - J. Avagliano
- Dermatology Unit IRCCS Humanitas Research Hospital Rozzano MI) USA
| | - M. Valenti
- Department of Biomedical Sciences Humanitas University Pieve Emanuele MI USA
- Dermatology Unit IRCCS Humanitas Research Hospital Rozzano MI) USA
| | - R. G. Borroni
- Department of Biomedical Sciences Humanitas University Pieve Emanuele MI USA
- Dermatology Unit IRCCS Humanitas Research Hospital Rozzano MI) USA
| | - A. Costanzo
- Department of Biomedical Sciences Humanitas University Pieve Emanuele MI USA
- Dermatology Unit IRCCS Humanitas Research Hospital Rozzano MI) USA
| | - A. Narcisi
- Dermatology Unit IRCCS Humanitas Research Hospital Rozzano MI) USA
| |
Collapse
|
18
|
Facco G, Mari A, Greco L, Forcellese A, Specchia N, Valenti M. New frontiers in pre-operative planning of complex spinal deformities. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00286-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
19
|
Longo R, Padovani R, Bertocchi L, De Denaro M, Milotti E, Rigon L, Valenti M, Sartor G, de Crescenzo S, Strigari L, Mascaro L, Turra A, Mazzocchi S, Torresin A, Pignoli E, Guidi G, De Ponti E, Brambilla M, Paiusco M, Diliberto R, Traino A, Soriani A, Buonamici FB, Stasi M, Trianni A, Scalchi P, Cavedon C, Francescon P, Ropolo R, Hrsak H. Training for the future: 8 years of Master of Advanced Studies in medical physics in Trieste. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00570-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
20
|
Mari A, Capretti C, Sbaraglia F, Cameli A, Pierini L, Misericordia M, Giovagnoni A, Galosi A, Valenti M. Dual energy CT combined with Infrared Spectroscopy: imaging to predict urinary stones composition and stiffness. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00227-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
21
|
Mariucci C, Vicenzi L, Costantini S, Di Carlo C, Cucciarelli F, Valenti M, Mantello G. PO-1288 Sequential external beam RT boost with two simultaneous dose levels in advanced cervical cancer. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07739-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
22
|
Patani F, Di Carlo C, Valenti M, Caravatta L, Costantini S, Fenu F, Panni V, Genovesi D, Mantello G. PO-1548 Liver deformability as residual error in liver stereotactic radiotherapy. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07999-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
23
|
Cucciarelli F, Arena E, Di Carlo C, Fenu F, Panni V, Vicenzi L, Parisotto M, Patani F, Valenti M, Mantello G. PO-1941 Use of Chabner XRT® Radiation Bra in a large-breasted patient: a case report. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08392-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Mazza M, Pino MC, Vagnetti R, Filocamo A, Attanasio M, Calvarese A, Valenti M. Intensive intervention for adolescents with autism spectrum disorder: comparison of three rehabilitation treatments. Int J Psychiatry Clin Pract 2021; 25:28-36. [PMID: 32744133 DOI: 10.1080/13651501.2020.1800042] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
INTRODUCTION Autism spectrum disorder (ASD) is a set of heterogeneous neurodevelopmental conditions, characterised by difficulties in social communication and restricted, repetitive behaviours and interests. There are several rehabilitative interventions for individuals with ASD but the evidence of their effectiveness is low or moderate overall. The transition phase of ASD individuals from adolescence to adulthood represents an important challenge. Adults with ASD struggle to access employment or independent living. METHODS In our study, we evaluated the effect of three different high-intensity interventions, namely Applied Behaviour Analysis (ABA), Treatment and Education of Autistic and Communication-Handicapped Children (TEACCH) and Behavioural Educational Intervention (BEI), in 93 ASD (levels 2 and 3) adolescents (age range 12-18 years). RESULTS Our results showed that all adolescents with ASD reported an improvement of core symptoms, regardless of the type of treatment. CONCLUSIONS A high intensity intervention ameliorates the core symptoms of ASD, enriching evidence of effectiveness regarding adolescents with ASD.KEY POINTSIndividuals with ASD need lifespan support and they struggle to access employment, independent living and community inclusion.There are several rehabilitative interventions for individuals with ASD but the evidence of their effectiveness in adolescents is insufficient.The main purpose of this study was to evaluate the possible enhancement produced by three intensive interventions (ABA, TEACCH, BEI) of symptom severity and adaptive functions.Results show that independently of the treatment, individuals with ASD decrease in ASD severity.Individuals who were treated with the BEI and TEACCH programmes reported improvements in the adaptive domains.
Collapse
Affiliation(s)
- M Mazza
- Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy
| | - M C Pino
- Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy
| | - R Vagnetti
- Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy
| | - A Filocamo
- Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy
| | - M Attanasio
- Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy
| | - A Calvarese
- Department of Mental Health, Abruzzo Region Health System, L'Aquila, Italy
| | - M Valenti
- Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy.,Regional Reference Centre for Autism, Abruzzo Region Health System, L'Aquila, Italy
| |
Collapse
|
25
|
Valenti M, Pavia G, Gargiulo L, Facheris P, Sanna F, Borroni RG, Costanzo A, Narcisi A. Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population. J DERMATOL TREAT 2021; 33:1638-1642. [PMID: 33555951 DOI: 10.1080/09546634.2021.1886231] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
INTRODUCTION This is an Italian single-center retrospective study evaluating safety and efficacy of biologic agents in psoriatic patients with a previous diagnosis of malignant cancer. AIM Management of moderate and severe psoriasis patients with a past medical history of malignancies could be difficult because biologic agents are historically associated with a presumptive increased risk of neoplastic reactivation or of a new incoming cancer. The aim of this study is to assess the safety of biologics in patients with a previous cancer diagnosis. MATERIAL AND METHODS The study analyzed 16 moderate to severe psoriasis patients with a diagnosis of malignant cancer in the previous 10 years treated with biologic agents for up to at least 96 weeks. In five of these patients, cancer was diagnosed in the previous 5 years. RESULTS We observed a rapid decrease in PASI (psoriasis area severity index) reaching a 90% improvement in 100% of patients. Oncologic follow up did not show any worsening or reactivation of cancer during the entire observation period. No new malignancies were observed in the analyzed sample. CONCLUSIONS Biologic agents in our experience have demonstrated to be safe and effective in psoriatic patients with a past medical history of malignant cancer.
Collapse
Affiliation(s)
- M Valenti
- Dermatology Unit, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.,Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - G Pavia
- Dermatology Unit, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.,Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - L Gargiulo
- Dermatology Unit, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.,Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - P Facheris
- Dermatology Unit, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.,Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - F Sanna
- Dermatology Unit, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy
| | - R G Borroni
- Dermatology Unit, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.,Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - A Costanzo
- Dermatology Unit, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.,Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - A Narcisi
- Dermatology Unit, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy
| |
Collapse
|
26
|
Poon E, Liang T, Jamin Y, Walz S, Kwok C, Hakkert A, Barker K, Urban Z, Thway K, Zeid R, Hallsworth A, Box G, Ebus ME, Licciardello MP, Sbirkov Y, Lazaro G, Calton E, Costa BM, Valenti M, De Haven Brandon A, Webber H, Tardif N, Almeida GS, Christova R, Boysen G, Richards MW, Barone G, Ford A, Bayliss R, Clarke PA, De Bono J, Gray NS, Blagg J, Robinson SP, Eccles SA, Zheleva D, Bradner JE, Molenaar J, Vivanco I, Eilers M, Workman P, Lin CY, Chesler L. Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. J Clin Invest 2020; 130:5875-5892. [PMID: 33016930 PMCID: PMC7598076 DOI: 10.1172/jci134132] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Accepted: 07/29/2020] [Indexed: 01/23/2023] Open
Abstract
The undruggable nature of oncogenic Myc transcription factors poses a therapeutic challenge in neuroblastoma, a pediatric cancer in which MYCN amplification is strongly associated with unfavorable outcome. Here, we show that CYC065 (fadraciclib), a clinical inhibitor of CDK9 and CDK2, selectively targeted MYCN-amplified neuroblastoma via multiple mechanisms. CDK9 - a component of the transcription elongation complex P-TEFb - bound to the MYCN-amplicon superenhancer, and its inhibition resulted in selective loss of nascent MYCN transcription. MYCN loss led to growth arrest, sensitizing cells for apoptosis following CDK2 inhibition. In MYCN-amplified neuroblastoma, MYCN invaded active enhancers, driving a transcriptionally encoded adrenergic gene expression program that was selectively reversed by CYC065. MYCN overexpression in mesenchymal neuroblastoma was sufficient to induce adrenergic identity and sensitize cells to CYC065. CYC065, used together with temozolomide, a reference therapy for relapsed neuroblastoma, caused long-term suppression of neuroblastoma growth in vivo, highlighting the clinical potential of CDK9/2 inhibition in the treatment of MYCN-amplified neuroblastoma.
Collapse
Affiliation(s)
- Evon Poon
- Division of Clinical Studies and
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Tong Liang
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA
| | - Yann Jamin
- Division of Radiotherapy and Imaging, ICR, London, United Kingdom
| | - Susanne Walz
- Core Unit Bioinformatics, Comprehensive Cancer Center Mainfranken and Theodor Boveri Institute, Biocenter, University of Wurzburg, Wurzburg, Germany
| | - Colin Kwok
- Division of Clinical Studies and
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Anne Hakkert
- Division of Clinical Studies and
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Karen Barker
- Division of Clinical Studies and
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Zuzanna Urban
- Division of Clinical Studies and
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Khin Thway
- Division of Molecular Pathology, ICR, London, and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Rhamy Zeid
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - Albert Hallsworth
- Division of Clinical Studies and
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Gary Box
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
- Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom
| | - Marli E. Ebus
- Prinses Maxima Center for Pediatric Oncology, Utrecht, Netherlands
| | - Marco P. Licciardello
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
- Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom
| | - Yordan Sbirkov
- Division of Clinical Studies and
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Glori Lazaro
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Elizabeth Calton
- Division of Clinical Studies and
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Barbara M. Costa
- Division of Clinical Studies and
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Melanie Valenti
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
- Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom
| | - Alexis De Haven Brandon
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
- Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom
| | - Hannah Webber
- Division of Clinical Studies and
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Nicolas Tardif
- Division of Clinical Studies and
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Gilberto S. Almeida
- Division of Clinical Studies and
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
- Division of Radiotherapy and Imaging, ICR, London, United Kingdom
| | | | | | - Mark W. Richards
- School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom
| | - Giuseppe Barone
- Division of Clinical Studies and
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Anthony Ford
- Division of Molecular Pathology, ICR, London, and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Richard Bayliss
- School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom
| | - Paul A. Clarke
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
- Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom
| | | | - Nathanael S. Gray
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA
| | - Julian Blagg
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
- Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom
| | | | - Suzanne A. Eccles
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
- Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom
| | | | - James E. Bradner
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
| | - Jan Molenaar
- Prinses Maxima Center for Pediatric Oncology, Utrecht, Netherlands
| | - Igor Vivanco
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| | - Martin Eilers
- Comprehensive Cancer Center Mainfranken and Theodor Boveri Institute, Biocenter, University of Wurzburg, Wurzburg, Germany
| | - Paul Workman
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
- Cancer Research UK, Cancer Therapeutics Unit, ICR, London, United Kingdom
| | - Charles Y. Lin
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA
| | - Louis Chesler
- Division of Clinical Studies and
- Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton, United Kingdom
| |
Collapse
|
27
|
Cucciarelli F, Parisotto M, Costantini S, Di Carlo C, Fenu F, Di Biase S, Vicenzi L, Di Benedetto M, Maucieri A, Montisci M, Morabito V, Valenti M, Maggi S, Mantello G. PO-0976: Left sided breast cancer patients and advanced radiotherapy techniques. A cardiac sparing approach. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00994-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Chan M, Liu H, Venencia D, Kadoya N, Alheet S, Toutaoui A, Krayenbuehl J, Sturt P, Leung R, Gevaert T, Valenti M, Skourou C, Modolell I, Martinez C, Farias R, Dorr J, Hanvey S, Waldron J, Grohmann M, Sylvia G. Multi-Center Planning Radiosurgery for Intracranial Metastases through Automation (MC-PRIMA). Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
29
|
Valenti M, Parisotto M, Angeletti F, Cucciarelli F, Mantello G, Maggi S. PO-1346: In-vivo surface dose measurements in breast cancer patient treated with helical radiation therapy. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01365-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Parisotto M, Valenti M, Mara G, Luca R, Vittoria Emanuela M, Kukiriza G, Aramini D, Maggi S. PO-1338: Validation of the rotation induced couch shift with the Machine Performance Check (MPC) tool. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01357-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
31
|
Di Carlo C, Valenti M, Costantini S, Cucciarelli F, Fenu F, Vicenzi L, Di Biase S, Maggi S, Mantello G. PO-1842: Set-up accuracy of BrainLab immobilization mask for intracranial stereotactic radiotherapy. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01860-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
32
|
Di Biase S, Fenu F, Di Carlo C, Costantini S, Cucciarelli F, Montisci M, Madia M, Vicenzi L, Giacometti M, Valenti M, Parisotto M, Maggi S, Mantello G. PO-1302: Management and safety report for patients with cardiac implantable electronic device in radiotherapy. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01320-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
33
|
Cusack M, Tyler A, Valenti M, Rogers J, MacLeod M. The Stirling Protocol - Putting the environment at the heart of prosperity and social inclusion. Sci Total Environ 2020; 737:140079. [PMID: 32783830 PMCID: PMC7301142 DOI: 10.1016/j.scitotenv.2020.140079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Revised: 06/05/2020] [Accepted: 06/06/2020] [Indexed: 06/11/2023]
Abstract
While the global coronavirus crisis impacts society and the economy in a myriad of ways, it provides, what is likely to be, a once in a lifetime opportunity for us to rethink our response to climate change. According to the 2020 Global Risk Register, extreme weather and climate action failure are the two most likely and impactful risks to the global economy, which now more than ever needs to be avoided. Addressing the major challenges that we face from climate change can often appear to conflict with economic priorities. Add to this the fact that environmental mitigation steps can inadvertently exclude sections of the population and the enormity and complexity of climate change responses can result in paralysis. In contrast, the Stirling Protocol provides the framework for rapid, effective action and comprises three pillars: Environment, Economy & Inclusion. By addressing and balancing these three pillars, the simple protocol can be adopted throughout organisations putting the environment at the heart of sustainable prosperity and inclusion and provide a benchmark for positive action.
Collapse
Affiliation(s)
- M Cusack
- Division of Biological & Environmental Science, Faculty of Natural Sciences, University of Stirling, Stirling FK9 4LA, UK.
| | - A Tyler
- Division of Biological & Environmental Science, Faculty of Natural Sciences, University of Stirling, Stirling FK9 4LA, UK
| | - M Valenti
- Scottish Enterprise, Atrium Court, Waterloo Street, Glasgow G2 6HQ, UK
| | - J Rogers
- Research & Innovation Services, University of Stirling, Stirling FK9 4LA, UK
| | - M MacLeod
- Faculty of Natural Sciences, University of Stirling, Stirling FK9 4LA, UK
| |
Collapse
|
34
|
De Haven Brandon A, Box G, Hallsworth A, Court W, Matthews N, Herodek B, Arteagabeitia AB, Valenti M, Kirkin V. Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice. Sci Rep 2020; 10:10799. [PMID: 32612269 PMCID: PMC7329846 DOI: 10.1038/s41598-020-67533-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Accepted: 06/09/2020] [Indexed: 12/14/2022] Open
Abstract
Ovarian cancer remains a significant challenge in women worldwide. Tumors of the high-grade serous carcinoma (HGSC) type represent the most common form of the disease. Development of new therapies for HGSC has been hampered by a paucity of preclinical models in which new drugs could be tested for target engagement and anti-tumor efficacy. Here, we systematically assessed in vivo growth of ovarian cancer cells, including six validated HGSC cell lines, in highly immunocompromised NSG mice by varying the injection site. We found that, with the exception of OVCAR3, HGSC cell lines COV318, COV362, KURAMOCHI, OVCAR4, and OVSAHO, generally demonstrate poor growth as either subcutaneous or intraperitoneal xenografts. Intrabursal injections performed with KURAMOCHI and COV362 cells did not improve tumor growth in vivo. Additional analysis revealed that OVSAHO and COV362 express moderate levels of estrogen receptor (ERα), which translated into improved growth of xenografts in the presence of 17β-Estradiol. Surprisingly, we also found that the growth of the widely used non-HGSC ovarian cell line SKOV3 could be significantly improved by estrogen supplementation. By describing successful establishment of estrogen-sensitive HGSC xenograft models, OVSAHO and COV362, this work will enable testing of novel therapies for this aggressive form of ovarian cancer.
Collapse
Affiliation(s)
- Alexis De Haven Brandon
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
| | - Gary Box
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
| | - Albert Hallsworth
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
| | - William Court
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
| | - Nicoll Matthews
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
| | - Balint Herodek
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
| | | | - Melanie Valenti
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
| | - Vladimir Kirkin
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK.
| |
Collapse
|
35
|
Valenti M, Gargiulo L, Pavia G, Facheris P, Borroni R, Narcisi A, Costanzo A. Reorganization of a Northern Italy dermatology department during the COVID-19 pandemic: is it temporary or the beginning of a new era in dermatology? J DERMATOL TREAT 2020; 33:597-598. [DOI: 10.1080/09546634.2020.1771255] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- M. Valenti
- Department of Dermatology, Humanitas Clinical and Research Center – IRCCS, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - L. Gargiulo
- Department of Dermatology, Humanitas Clinical and Research Center – IRCCS, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - G. Pavia
- Department of Dermatology, Humanitas Clinical and Research Center – IRCCS, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - P. Facheris
- Department of Dermatology, Humanitas Clinical and Research Center – IRCCS, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - R. Borroni
- Department of Dermatology, Humanitas Clinical and Research Center – IRCCS, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
| | - A. Narcisi
- Department of Dermatology, Humanitas Clinical and Research Center – IRCCS, Milan, Italy
| | - A. Costanzo
- Department of Dermatology, Humanitas Clinical and Research Center – IRCCS, Milan, Italy
- Department of Biomedical Sciences, Humanitas University, Milan, Italy
| |
Collapse
|
36
|
Andrejeva G, Gowan S, Lin G, Wong Te Fong ACLF, Shamsaei E, Parkes HG, Mui J, Raynaud FI, Asad Y, Vizcay-Barrena G, Nikitorowicz-Buniak J, Valenti M, Howell L, Fleck RA, Martin LA, Kirkin V, Leach MO, Chung YL. De novo phosphatidylcholine synthesis is required for autophagosome membrane formation and maintenance during autophagy. Autophagy 2020; 16:1044-1060. [PMID: 31517566 PMCID: PMC7469489 DOI: 10.1080/15548627.2019.1659608] [Citation(s) in RCA: 55] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2017] [Revised: 07/31/2019] [Accepted: 08/12/2019] [Indexed: 01/13/2023] Open
Abstract
Macroautophagy/autophagy can enable cancer cells to withstand cellular stress and maintain bioenergetic homeostasis by sequestering cellular components into newly formed double-membrane vesicles destined for lysosomal degradation, potentially affecting the efficacy of anti-cancer treatments. Using 13C-labeled choline and 13C-magnetic resonance spectroscopy and western blotting, we show increased de novo choline phospholipid (ChoPL) production and activation of PCYT1A (phosphate cytidylyltransferase 1, choline, alpha), the rate-limiting enzyme of phosphatidylcholine (PtdCho) synthesis, during autophagy. We also discovered that the loss of PCYT1A activity results in compromised autophagosome formation and maintenance in autophagic cells. Direct tracing of ChoPLs with fluorescence and immunogold labeling imaging revealed the incorporation of newly synthesized ChoPLs into autophagosomal membranes, endoplasmic reticulum (ER) and mitochondria during anticancer drug-induced autophagy. Significant increase in the colocalization of fluorescence signals from the newly synthesized ChoPLs and mCherry-MAP1LC3/LC3 (microtubule-associated protein 1 light chain 3) was also found on autophagosomes accumulating in cells treated with autophagy-modulating compounds. Interestingly, cells undergoing active autophagy had an altered ChoPL profile, with longer and more unsaturated fatty acid/alcohol chains detected. Our data suggest that de novo synthesis may be required to increase autophagosomal ChoPL content and alter its composition, together with replacing phospholipids consumed from other organelles during autophagosome formation and turnover. This addiction to de novo ChoPL synthesis and the critical role of PCYT1A may lead to development of agents targeting autophagy-induced drug resistance. In addition, fluorescence imaging of choline phospholipids could provide a useful way to visualize autophagosomes in cells and tissues. ABBREVIATIONS AKT: AKT serine/threonine kinase; BAX: BCL2 associated X, apoptosis regulator; BECN1: beclin 1; ChoPL: choline phospholipid; CHKA: choline kinase alpha; CHPT1: choline phosphotransferase 1; CTCF: corrected total cell fluorescence; CTP: cytidine-5'-triphosphate; DCA: dichloroacetate; DMEM: dulbeccos modified Eagles medium; DMSO: dimethyl sulfoxide; EDTA: ethylenediaminetetraacetic acid; ER: endoplasmic reticulum; GDPD5: glycerophosphodiester phosphodiesterase domain containing 5; GFP: green fluorescent protein; GPC: glycerophosphorylcholine; HBSS: hanks balances salt solution; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; LPCAT1: lysophosphatidylcholine acyltransferase 1; LysoPtdCho: lysophosphatidylcholine; MRS: magnetic resonance spectroscopy; MTORC1: mechanistic target of rapamycin kinase complex 1; PCho: phosphocholine; PCYT: choline phosphate cytidylyltransferase; PLA2: phospholipase A2; PLB: phospholipase B; PLC: phospholipase C; PLD: phospholipase D; PCYT1A: phosphate cytidylyltransferase 1, choline, alpha; PI3K: phosphoinositide-3-kinase; pMAFs: pancreatic mouse adult fibroblasts; PNPLA6: patatin like phospholipase domain containing 6; Pro-Cho: propargylcholine; Pro-ChoPLs: propargylcholine phospholipids; PtdCho: phosphatidylcholine; PtdEth: phosphatidylethanolamine; PtdIns3P: phosphatidylinositol-3-phosphate; RPS6: ribosomal protein S6; SCD: stearoyl-CoA desaturase; SEM: standard error of the mean; SM: sphingomyelin; SMPD1/SMase: sphingomyelin phosphodiesterase 1, acid lysosomal; SGMS: sphingomyelin synthase; WT: wild-type.
Collapse
Affiliation(s)
- Gabriela Andrejeva
- Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research London and Royal Marsden Hospital, London, UK
| | - Sharon Gowan
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research London, London, UK
| | - Gigin Lin
- Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research London and Royal Marsden Hospital, London, UK
- Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Anne-Christine LF Wong Te Fong
- Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research London and Royal Marsden Hospital, London, UK
| | - Elham Shamsaei
- Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research London and Royal Marsden Hospital, London, UK
| | - Harry G. Parkes
- Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research London and Royal Marsden Hospital, London, UK
| | - James Mui
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research London, London, UK
| | - Florence I. Raynaud
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research London, London, UK
| | - Yasmin Asad
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research London, London, UK
| | | | | | - Melanie Valenti
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research London, London, UK
| | - Louise Howell
- Molecular Pathology, The Institute of Cancer Research London, London, UK
| | - Roland A. Fleck
- Centre for Ultrastructural Imaging, King’s College London, London, UK
| | - Lesley-Ann Martin
- Breast Cancer Research, The Institute of Cancer Research London, London, UK
| | - Vladimir Kirkin
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research London, London, UK
| | - Martin O. Leach
- Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research London and Royal Marsden Hospital, London, UK
| | - Yuen-Li Chung
- Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research London and Royal Marsden Hospital, London, UK
| |
Collapse
|
37
|
Murru A, Colom F, Nivoli A, Pacchiarotti I, Valenti M, Vieta E. When should mood stabilizers be withdrawn due to lack of efficacy? Some methodological considerations. Eur Psychiatry 2020; 26:183-6. [DOI: 10.1016/j.eurpsy.2010.09.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2010] [Revised: 09/27/2010] [Accepted: 09/28/2010] [Indexed: 02/04/2023] Open
Abstract
AbstractMaintenance therapy in bipolar disorder is primarily aimed at preventing recurrence of acute episodes. Clinicians often decide on the basis of their own experience whether mood stabilizer (MS) is properly satisfying the objective of preventing a relapse/recurrence. Evidence-based data seem far from clinical practice in assessing a MS efficacy, as they mainly focus on a drug's efficacy to first relapse and not considering the patient's course of illness. The problem of assessing MS's efficacy seems further complicated when considering combination therapy, which, due to lack of evidence-based data, economical aspects, attitude of clinicians and legal issues may bring to cumulative prescriptions. Nowadays, the drug therapy for a bipolar patient is usually tailored after longitudinal observation of his specific course of illness. The course of illness should be considered also when choosing practical criteria for the suspension of a MS due to lack of efficacy. The authors propose some preliminary criteria which may help clinicians evaluating whether a mood stabilizer is being useful or not, dividing possible outcomes and suggesting subsequent therapeutic steps in the optimization of a patient's treatment.
Collapse
|
38
|
Kennedy C, Higginson C, Valenti M, Ibrahim K, Knarr B, Ryan R, Higginson J. A-12 Neuroticism and Extraversion are Related to Dual Task Postural Stability in Healthy Young Adults. Arch Clin Neuropsychol 2019. [DOI: 10.1093/arclin/acz034.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Objective
The relation between personality and postural stability has received little attention. This study addressed whether neuroticism and extraversion are related to changes in postural stability and cognitive functioning during a standing balance task.
Method
Thirty-two healthy young adults completed a personality measure and two cognitive tasks, a 2-back task and a weather prediction task (WPT), both while seated and in tandem stance on a foam mat. Sway was quantified via normalized path lengths, and correlation coefficients were calculated between neuroticism, extraversion and dual task changes in postural stability and cognitive functioning.
Results
Consistent with predictions, higher neuroticism was related to increased dual task sway during the 2-back task, r = 0.40, p = 0.023, and lower extraversion was related to increased dual task sway during the WPT, r = -0.43, p = 0.013.
Conclusions
The results suggest that personality is related to postural stability in healthy young adults and that personality should be considered in the prediction of individuals at risk for falling or in the treatment of individuals with balance difficulties. The task-specific nature of the relation is discussed and may be due to differences in anxiety or underlying brain mechanisms between high neuroticism and low extraversion.
Collapse
|
39
|
Wagner S, Vlachogiannis G, De Haven Brandon A, Valenti M, Box G, Jenkins L, Mancusi C, Self A, Manodoro F, Assiotis I, Robinson P, Chauhan R, Rust AG, Matthews N, Eason K, Khan K, Starling N, Cunningham D, Sadanandam A, Isacke CM, Kirkin V, Valeri N, Whittaker SR. Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. Oncogene 2019; 38:5746. [PMID: 31147600 PMCID: PMC7608239 DOI: 10.1038/s41388-019-0835-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Steve Wagner
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | | | | | - Melanie Valenti
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | - Gary Box
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | - Liam Jenkins
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK
| | - Caterina Mancusi
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | - Annette Self
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | | | - Ioannis Assiotis
- Tumour Profiling Unit, The Institute of Cancer Research, London, UK
| | - Penny Robinson
- Tumour Profiling Unit, The Institute of Cancer Research, London, UK
| | - Ritika Chauhan
- Tumour Profiling Unit, The Institute of Cancer Research, London, UK
| | - Alistair G Rust
- Tumour Profiling Unit, The Institute of Cancer Research, London, UK
| | - Nik Matthews
- Tumour Profiling Unit, The Institute of Cancer Research, London, UK
| | - Kate Eason
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK
| | - Khurum Khan
- Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK
| | - Naureen Starling
- Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK
| | - David Cunningham
- Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK
| | - Anguraj Sadanandam
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK
| | - Clare M Isacke
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK
| | - Vladimir Kirkin
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | - Nicola Valeri
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK.,Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK
| | - Steven R Whittaker
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
| |
Collapse
|
40
|
Carvalho D, Taylor KR, Olaciregui NG, Molinari V, Clarke M, Mackay A, Ruddle R, Henley A, Valenti M, Hayes A, Brandon ADH, Eccles SA, Raynaud F, Boudhar A, Monje M, Popov S, Moore AS, Mora J, Cruz O, Vinci M, Brennan PE, Bullock AN, Carcaboso AM, Jones C. ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. Commun Biol 2019; 2:156. [PMID: 31098401 PMCID: PMC6509210 DOI: 10.1038/s42003-019-0420-8] [Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Accepted: 04/08/2019] [Indexed: 02/07/2023] Open
Abstract
Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brainstem tumour, with a quarter of patients harbouring somatic mutations in ACVR1, encoding the serine/threonine kinase ALK2. Despite being an amenable drug target, little has been done to-date to systematically evaluate the role of ACVR1 in DIPG, nor to screen currently available inhibitors in patient-derived tumour models. Here we show the dependence of DIPG cells on the mutant receptor, and the preclinical efficacy of two distinct chemotypes of ALK2 inhibitor in vitro and in vivo. We demonstrate the pyrazolo[1,5-a]pyrimidine LDN-193189 and the pyridine LDN-214117 to be orally bioavailable and well-tolerated, with good brain penetration. Treatment of immunodeprived mice bearing orthotopic xenografts of H3.3K27M, ACVR1R206H mutant HSJD-DIPG-007 cells with 25 mg/kg LDN-193189 or LDN-214117 for 28 days extended survival compared with vehicle controls. Development of ALK2 inhibitors with improved potency, selectivity and advantageous pharmacokinetic properties may play an important role in therapy for DIPG patients.
Collapse
Grants
- Wellcome Trust
- C13468/A14078 Cancer Research UK
- 106169/ZZ14/Z Wellcome Trust
- CHILDREN with CANCER UK
- This work was supported by Children with Cancer UK, Abbie’s Army and the DIPG Collaborative, the Lyla Nsouli Foundation and Lucas’ Legacy, the McKenna Claire Foundation and Fondo Alicia Pueyo. The Queensland Children’s Tumour Bank is supported by the Children’s Hospital Foundation. We thank Louise Howell (ICR) for excellent technical assistance. This work was supported by the Xarxa de Bancs de Tumors de Catalunya (XBTC), sponsored by Pla Director d’Oncologia de Catalunya. AMC acknowledges funding from ISCIII-FEDER (CP13/00189). A.B. and A.N.B acknowledge funding from the Amateurs Trust, Roemex Ltd and FOP Friends. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, MSD, Merck KGaA, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP, Takeda and Wellcome [106169/ZZ14/Z]. This study makes use of data generated by Cancer Research UK Genomics Initiative (C13468/A14078). The authors acknowledge NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden and the ICR.
Collapse
Affiliation(s)
- Diana Carvalho
- Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK
| | - Kathryn R. Taylor
- Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK
- Stanford University School of Medicine, Stanford, 94305 CA USA
| | | | - Valeria Molinari
- Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK
| | - Matthew Clarke
- Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK
| | - Alan Mackay
- Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK
| | - Ruth Ruddle
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK
| | - Alan Henley
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK
| | - Melanie Valenti
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK
| | - Angela Hayes
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK
| | | | - Suzanne A. Eccles
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK
| | - Florence Raynaud
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK
| | - Aicha Boudhar
- Structural Genomics Consortium, University of Oxford, Oxford, OX3 7DQ UK
- Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, OX3 7FZ UK
| | - Michelle Monje
- Stanford University School of Medicine, Stanford, 94305 CA USA
| | - Sergey Popov
- Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK
- Department of Cellular Pathology, University Hospital of Wales, Cardiff, CF14 4XW UK
| | - Andrew S. Moore
- Diamantina Institute and Child Health Research Centre, The University of Queensland, Brisbane, QLD 4101 Australia
- Oncology Service, Queensland Children’s Hospital, Brisbane, QLD 4029 Australia
| | - Jaume Mora
- Institut de Recerca Sant Joan de Deu, Barcelona, 08950 Esplugues de Llobregat Spain
| | - Ofelia Cruz
- Institut de Recerca Sant Joan de Deu, Barcelona, 08950 Esplugues de Llobregat Spain
| | - Mara Vinci
- Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK
- Bambino Gesù Children’s Hospital, Rome, 00165 Roma RM Italy
| | - Paul E. Brennan
- Structural Genomics Consortium, University of Oxford, Oxford, OX3 7DQ UK
- Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, OX3 7FZ UK
| | - Alex N. Bullock
- Structural Genomics Consortium, University of Oxford, Oxford, OX3 7DQ UK
| | | | - Chris Jones
- Divisions of Molecular Pathology, The Institute of Cancer Research, London, SM2 5NG UK
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG UK
| |
Collapse
|
41
|
Wagner S, Vlachogiannis G, De Haven Brandon A, Valenti M, Box G, Jenkins L, Mancusi C, Self A, Manodoro F, Assiotis I, Robinson P, Chauhan R, Rust AG, Matthews N, Eason K, Khan K, Starling N, Cunningham D, Sadanandam A, Isacke CM, Kirkin V, Valeri N, Whittaker SR. Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. Oncogene 2019; 38:1717-1733. [PMID: 30353166 PMCID: PMC6462854 DOI: 10.1038/s41388-018-0554-z] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2018] [Revised: 09/14/2018] [Accepted: 09/14/2018] [Indexed: 12/17/2022]
Abstract
Despite showing clinical activity in BRAF-mutant melanoma, the MEK inhibitor (MEKi) trametinib has failed to show clinical benefit in KRAS-mutant colorectal cancer. To identify mechanisms of resistance to MEKi, we employed a pharmacogenomic analysis of MEKi-sensitive versus MEKi-resistant colorectal cancer cell lines. Strikingly, interferon- and inflammatory-related gene sets were enriched in cell lines exhibiting intrinsic and acquired resistance to MEK inhibition. The bromodomain inhibitor JQ1 suppressed interferon-stimulated gene (ISG) expression and in combination with MEK inhibitors displayed synergistic effects and induced apoptosis in MEKi-resistant colorectal cancer cell lines. ISG expression was confirmed in patient-derived organoid models, which displayed resistance to trametinib and were resensitized by JQ1 co-treatment. In in vivo models of colorectal cancer, combination treatment significantly suppressed tumor growth. Our findings provide a novel explanation for the limited response to MEK inhibitors in KRAS-mutant colorectal cancer, known for its inflammatory nature. Moreover, the high expression of ISGs was associated with significantly reduced survival of colorectal cancer patients. Excitingly, we have identified novel therapeutic opportunities to overcome intrinsic and acquired resistance to MEK inhibition in colorectal cancer.
Collapse
Affiliation(s)
- Steve Wagner
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | | | | | - Melanie Valenti
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | - Gary Box
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | - Liam Jenkins
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK
| | - Caterina Mancusi
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | - Annette Self
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | | | - Ioannis Assiotis
- Tumour Profiling Unit, The Institute of Cancer Research, London, UK
| | - Penny Robinson
- Tumour Profiling Unit, The Institute of Cancer Research, London, UK
| | - Ritika Chauhan
- Tumour Profiling Unit, The Institute of Cancer Research, London, UK
| | - Alistair G Rust
- Tumour Profiling Unit, The Institute of Cancer Research, London, UK
| | - Nik Matthews
- Tumour Profiling Unit, The Institute of Cancer Research, London, UK
| | - Kate Eason
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK
| | - Khurum Khan
- Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK
| | - Naureen Starling
- Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK
| | - David Cunningham
- Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK
| | - Anguraj Sadanandam
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK
| | - Clare M Isacke
- Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK
| | - Vladimir Kirkin
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | - Nicola Valeri
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK
- Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK
| | - Steven R Whittaker
- Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
| |
Collapse
|
42
|
Banerji U, Sain N, Sharp SY, Valenti M, Asad Y, Ruddle R, Raynaud F, Walton M, Eccles SA, Judson I, Jackman AL, Workman P. Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol 2018; 82:911-912. [PMID: 30173339 DOI: 10.1007/s00280-018-3674-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
The corresponding author of this article has informed us of concerns about the immunoblots in Fig. 2 which were carried out in the collaborating laboratory of Professor Ann Jackman.
Collapse
Affiliation(s)
- Udai Banerji
- Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
| | - Nivedita Sain
- Section of Medicine, Haddow Laboratories, The Institute of Cancer Research, Sutton, UK
| | - Swee Y Sharp
- Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
| | - Melanie Valenti
- Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
| | - Yasmin Asad
- Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
| | - Ruth Ruddle
- Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
| | - Florence Raynaud
- Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
| | - Michael Walton
- Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
| | - Suzanne A Eccles
- Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
| | - Ian Judson
- Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
| | - Ann L Jackman
- Section of Medicine, Haddow Laboratories, The Institute of Cancer Research, Sutton, UK
| | - Paul Workman
- Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
| |
Collapse
|
43
|
Woodward H, Innocenti P, Cheung KMJ, Hayes A, Roberts J, Henley AT, Faisal A, Mak GWY, Box G, Westwood IM, Cronin N, Carter M, Valenti M, De Haven Brandon A, O’Fee L, Saville H, Schmitt J, Burke R, Broccatelli F, van Montfort RLM, Raynaud FI, Eccles SA, Linardopoulos S, Blagg J, Hoelder S. Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N 2-(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl- N 8-neopentylpyrido[3,4- d]pyrimidine-2,8-diamine (BOS172722). J Med Chem 2018; 61:8226-8240. [PMID: 30199249 PMCID: PMC6166229 DOI: 10.1021/acs.jmedchem.8b00690] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Indexed: 12/22/2022]
Abstract
Monopolar spindle 1 (MPS1) occupies a central role in mitosis and is one of the main components of the spindle assembly checkpoint. The MPS1 kinase is an attractive cancer target, and herein, we report the discovery of the clinical candidate BOS172722. The starting point for our work was a series of pyrido[3,4- d]pyrimidine inhibitors that demonstrated excellent potency and kinase selectivity but suffered from rapid turnover in human liver microsomes (HLM). Optimizing HLM stability proved challenging since it was not possible to identify a consistent site of metabolism and lowering lipophilicity proved unsuccessful. Key to overcoming this problem was the finding that introduction of a methyl group at the 6-position of the pyrido[3,4- d]pyrimidine core significantly improved HLM stability. Met ID studies suggested that the methyl group suppressed metabolism at the distant aniline portion of the molecule, likely by blocking the preferred pharmacophore through which P450 recognized the compound. This work ultimately led to the discovery of BOS172722 as a Phase 1 clinical candidate.
Collapse
Affiliation(s)
- Hannah
L. Woodward
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Paolo Innocenti
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Kwai-Ming J. Cheung
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Angela Hayes
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Jennie Roberts
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Alan T. Henley
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Amir Faisal
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Grace Wing-Yan Mak
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Gary Box
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Isaac M. Westwood
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
- Division
of Structural Biology, The Institute of
Cancer Research, London SW3 6JB, United Kingdom
| | - Nora Cronin
- Division
of Structural Biology, The Institute of
Cancer Research, London SW3 6JB, United Kingdom
| | - Michael Carter
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Melanie Valenti
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Alexis De Haven Brandon
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Lisa O’Fee
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Harry Saville
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Jessica Schmitt
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Rosemary Burke
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Fabio Broccatelli
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Rob L. M. van Montfort
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
- Division
of Structural Biology, The Institute of
Cancer Research, London SW3 6JB, United Kingdom
| | - Florence I. Raynaud
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Suzanne A. Eccles
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Spiros Linardopoulos
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
- The
Breakthrough Breast Cancer Research Centre, Division of Breast Cancer
Research, The Institute of Cancer Research, London SW3 6JB, United Kingdom
| | - Julian Blagg
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - Swen Hoelder
- Cancer
Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom
| |
Collapse
|
44
|
Valenti M, Campanelli A, Parisotto M, Maggi S. Cine 4DCT imaging artifacts: Quantification and correlations with scanning parameters and target kinetics. Phys Med 2018; 52:133-142. [DOI: 10.1016/j.ejmp.2018.07.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/10/2018] [Revised: 07/19/2018] [Accepted: 07/21/2018] [Indexed: 12/25/2022] Open
|
45
|
Woodward H, Innocenti P, Cheung KMJ, Naud S, Faisal A, Mak GW, Hayes A, O'Fee L, Saville H, Brandon ADH, Roberts J, Box G, Valenti M, Heneley AT, Walsh K, Burke R, Eccles SA, Raynaud FI, Montfort RLV, Blagg J, Linardopoulos S, Hoelder S. Abstract 1651: In vitro and in vivo profile of the preclinical candidate and MPS1 kinase inhibitor CCT289346. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-1651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The mitotic kinase MPS1 (also known as TTK) is one of the main components of the spindle assembly checkpoint. MPS1 is required for chromosome alignment and kinetochore-microtubule error correction. Cancer cells are dependent on MPS1 to cope with chromosomal instability resulting from aberrant numbers of chromosomes. Moreover, MPS1 has been found to be deregulated in a large number of tumor types. MPS1 kinase inhibitors induce cancer cells to prematurely exit mitosis with incorrectly attached and unaligned chromosomes, causing severe chromosome mis-segregation, aneuploidy and cell death. These data stimulated us to pursue MPS1 as a cancer target. Extensive work by us and other groups has shown that MPS1 inhibitors are effective against a variety of cancers, particularly when used in combination with other drugs, such as paclitaxel. Here we disclose CCT289346, an MPS1 inhibitor currently completing late stage preclinical development. We describe the final stages of chemical optimisation and the data driven selection and nomination of CCT289346 as our preclinical candidate. We report key in vitro and in vivo preclinical data such as kinase profiling, PK in mouse, rat and dog, PK/PD relationship and efficacy in different in vivo models.
Citation Format: Hannah Woodward, Paolo Innocenti, Kwai-Ming J. Cheung, Sébastien Naud, Amir Faisal, Grace W. Mak, Angela Hayes, Lisa O'Fee, Harry Saville, Alexis De Haven Brandon, Jennie Roberts, Gary Box, Melanie Valenti, Alan T. Heneley, Katie Walsh, Rosemary Burke, Suzanne A. Eccles, Florence I. Raynaud, Rob L. van Montfort, Julian Blagg, Spiros Linardopoulos, Swen Hoelder. In vitro and in vivo profile of the preclinical candidate and MPS1 kinase inhibitor CCT289346 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1651.
Collapse
Affiliation(s)
| | | | | | | | - Amir Faisal
- Institute of Cancer Research, London, United Kingdom
| | - Grace W. Mak
- Institute of Cancer Research, London, United Kingdom
| | - Angela Hayes
- Institute of Cancer Research, London, United Kingdom
| | - Lisa O'Fee
- Institute of Cancer Research, London, United Kingdom
| | - Harry Saville
- Institute of Cancer Research, London, United Kingdom
| | | | | | - Gary Box
- Institute of Cancer Research, London, United Kingdom
| | | | | | - Katie Walsh
- Institute of Cancer Research, London, United Kingdom
| | | | | | | | | | - Julian Blagg
- Institute of Cancer Research, London, United Kingdom
| | | | - Swen Hoelder
- Institute of Cancer Research, London, United Kingdom
| |
Collapse
|
46
|
Wagner S, Vlachogiannis G, Brandon ADH, Valenti M, Box G, Jenkins L, Mancusi C, Self A, Chauhan R, Rust A, Matthews N, Eason K, Sadanandam A, Isacke C, Kirkin V, Valeri N, Whittaker SR. Abstract LB-094: Suppression of inflammatory gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-lb-094] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Despite showing clinical activity in BRAF-mutant melanoma, the MEK inhibitor (MEKi) trametinib failed to show clinical benefit in KRAS-mutant colorectal cancer. To identify mechanisms of resistance to MEK inhibition we identified gene expression differences between MEKi-sensitive and MEKi-resistant colorectal cancer cell lines. Strikingly, inflammation-related gene sets were the most significantly enriched in cell lines exhibiting intrinsic or acquired resistance to MEK inhibition. The bromodomain inhibitor JQ1 suppressed inflammatory gene expression and in combination with MEK inhibitors displayed synergistic anti-proliferative activity, inhibited colony formation and induced apoptosis in colorectal cancer cell lines. NFkB activation was greater in cell lines resistant to MEK inhibition and JQ1 treatment suppressed TNF-induced translocation of NFkB to the nucleus. Resistance to MEK inhibition could be induced by inflammatory cytokines or by conditioned medium from macrophage cultures and was associated with greater NFkB activation. In 2-dimensional cell culture and in 3-dimensional spheroid models of colorectal cancer, resistance to trametinib was readily established; however, co-treatment of cells with JQ1 and trametinib suppressed the emergence of resistant populations. Notably, high inflammatory gene expression was confirmed in patient-derived organoid (PDO) models of colorectal cancer, which displayed resistance to trametinib. JQ1 treatment of PDOs suppressed inflammatory gene expression and showed synergistic anti-proliferative activity in combination with trametinib. Combination treatment of in vivo models of KRAS-mutant colorectal cancer significantly suppressed tumor growth. Our findings provide a potential explanation for the limited response to MEK inhibitors in KRAS-mutant colorectal cancer, where a highly inflammatory environment may prime cells to be resistant to MEK inhibition. Moreover, the high expression of inflammatory genes was associated with significantly reduced survival of colorectal cancer patients. Excitingly, this opens novel therapeutic opportunities to overcome intrinsic and acquired resistance to MEK inhibition in colorectal cancer.
Citation Format: Steve Wagner, George Vlachogiannis, Alexis de Haven Brandon, Melanie Valenti, Gary Box, Liam Jenkins, Caterina Mancusi, Annette Self, Ritika Chauhan, Alistair Rust, Nik Matthews, Kate Eason, Anguraj Sadanandam, Clare Isacke, Vladimir Kirkin, Nicola Valeri, Steven R. Whittaker. Suppression of inflammatory gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-094.
Collapse
Affiliation(s)
- Steve Wagner
- The Institute of Cancer Research, London, United Kingdom
| | | | | | | | - Gary Box
- The Institute of Cancer Research, London, United Kingdom
| | - Liam Jenkins
- The Institute of Cancer Research, London, United Kingdom
| | | | - Annette Self
- The Institute of Cancer Research, London, United Kingdom
| | - Ritika Chauhan
- The Institute of Cancer Research, London, United Kingdom
| | - Alistair Rust
- The Institute of Cancer Research, London, United Kingdom
| | - Nik Matthews
- The Institute of Cancer Research, London, United Kingdom
| | - Kate Eason
- The Institute of Cancer Research, London, United Kingdom
| | | | - Clare Isacke
- The Institute of Cancer Research, London, United Kingdom
| | | | - Nicola Valeri
- The Institute of Cancer Research, London, United Kingdom
| | | |
Collapse
|
47
|
Abstract
Children with autism are characterized by an impairment of social interaction and repetitive patterns of behaviour. Autism is a heterogeneous span of disorders with unknown aetiology. Research has grown significantly and has suggested that environmental risk factors acting during the prenatal period could influence the neurodevelopment of offspring. The literature suggests that the maternal diet during pregnancy has a fundamental role in the etiopathogenesis of autism. Indeed, a maternal diet that is high in some nutrients has been associated with an increase or reduction in the risk of develop Autism Spectrum Disorders (ASD). The diet of ASD children is also a key factor for the worsening of ASD symptoms. Children with autism have food selectivity and limited diets due to smell, taste, or other characteristics of foods. This determines eating routines and food intake patterns, with consequent deficiency or excess of some aliments. Several studies have tried to show a possible relationship between nutritional status and autism. In this review we describe, emphasizing the limits and benefits, the main current empirical studies that have examined the role of maternal diet during gestation and diet of ASD children as modifiable risk factors at the base of development or worsening of symptoms of autism.
Collapse
Affiliation(s)
- S Peretti
- Department of Applied Clinical Sciences and Biotechnology, Section of Clinical Epidemiology and Environmental Medicine, University of L'Aquila, Via Vetoio, Località Coppito, 67100 L'Aquila, Italy.,Abruzzo Region Health System, Reference Regional Centre for Autism, L'Aquila, Italy
| | - M Mariano
- Department of Applied Clinical Sciences and Biotechnology, Section of Clinical Epidemiology and Environmental Medicine, University of L'Aquila, Via Vetoio, Località Coppito, 67100 L'Aquila, Italy.,Abruzzo Region Health System, Reference Regional Centre for Autism, L'Aquila, Italy
| | - C Mazzocchetti
- Department of Pediatrics, San Salvatore Hospital, University of L'Aquila, Località Coppito, L'Aquila 67100, Italy
| | - M Mazza
- Department of Applied Clinical Sciences and Biotechnology, Section of Clinical Epidemiology and Environmental Medicine, University of L'Aquila, Via Vetoio, Località Coppito, 67100 L'Aquila, Italy.,Abruzzo Region Health System, Reference Regional Centre for Autism, L'Aquila, Italy
| | - M C Pino
- Department of Applied Clinical Sciences and Biotechnology, Section of Clinical Epidemiology and Environmental Medicine, University of L'Aquila, Via Vetoio, Località Coppito, 67100 L'Aquila, Italy.,Abruzzo Region Health System, Reference Regional Centre for Autism, L'Aquila, Italy
| | - A Verrotti Di Pianella
- Department of Applied Clinical Sciences and Biotechnology, Section of Clinical Epidemiology and Environmental Medicine, University of L'Aquila, Via Vetoio, Località Coppito, 67100 L'Aquila, Italy.,Department of Pediatrics, San Salvatore Hospital, University of L'Aquila, Località Coppito, L'Aquila 67100, Italy
| | - M Valenti
- Department of Applied Clinical Sciences and Biotechnology, Section of Clinical Epidemiology and Environmental Medicine, University of L'Aquila, Via Vetoio, Località Coppito, 67100 L'Aquila, Italy.,Abruzzo Region Health System, Reference Regional Centre for Autism, L'Aquila, Italy
| |
Collapse
|
48
|
Dionisio P, Valenti M, Bajardi P. Monitoring of Central Dual-Lumen Catheter Placement in Haemodialysis by Endocavitary Electrocardiography: A Simple and Safe Technique for the Clinical Nephrologist. J Vasc Access 2018; 1:88-92. [PMID: 17638233 DOI: 10.1177/112972980000100304] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Complications in the placement of central venous catheter (CVC) may occur in up to 20% of cases. The catheter can be misplaced in the contralateral brachiocephalic vein, the ipsi or controlateral internal jugular vein, and usually a chest X-ray is necessary to evaluate its location. We believe that the best technique, first described by Serafini et al, to establish the position of a CVC is the endocavitary electrocardiography (EC-ECG) and its employment is recommended in all uraemic patients requiring haemodialysis. This technique uses the tip of the CVC as reference lead in a standard electrocardiograph. The best use of this technique has been obtained by echotomographic visualization of the internal jugular vein executed just before transcutaneous puncture of the vessel. From 1991 to December 1999 we have successfully applied this technique in CVC placement in 612 patients requiring haemodialysis. In our opinion, this method is a safe and simple technique that avoids the need for thoracic X-ray controls and time lost waiting for radiographs that prolong the start of the haemodialysis session. According to our experience, we believe that the EC-ECG technique is a method in compliance with Food and Drug Administration guidelines regarding catheter tip location in uraemic patients.
Collapse
Affiliation(s)
- P Dionisio
- Department of Nephrology and Dialysis, Ospedale degli Infermi, Biella - Italy
| | | | | |
Collapse
|
49
|
Dionisio P, Cavatorta F, Zollo A, Valenti M, Chiappini N, Bajardi P. The Placement of Central Venous Catheters in Hemodialysis: Role of the Endocavitary Electrocardiographic Trace. Case Reports and Literature Review. J Vasc Access 2018; 2:80-8. [PMID: 17638266 DOI: 10.1177/112972980100200211] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
At present, the placement of a central venous catheter is becoming more and more a routine procedure nevertheless it involves different operators in fields such as oncology, nutrition, nephrology, and emergency medicine. It is well known that complications in the placement of CVC may occur in up to 20% of cases. One fifth of the catheters may result to be misplaced either in the internal omolateral jugular vein or in the innominate vein or in the controlateral brachiocephalic veins and usually a chest radiogram is necessary to evaluate its location. On the basis of 10 years of experience including more than 1,000 CVC placements, we now believe that endocavitary electrocardiography EC-ECG, initially studied and applied by Dr. Serafini, constitutes the best technique, more secure and more comfortable for the patient, to verify the position of the tip of a CVC. The technique EC-ECG, very simple and secure, utilizes the CVC as an endocavitary electrode. This is connected to a standard electrocardiograph, the same one to which the patient is connected during the placement of the CVC, and provides, in derivation V1 or D3, an electrocardiographic pattern extremely sensitive to the position of the catheter tip. From December 1991 to December 2000, this technique has been used successfully in our departments of nephrology and applied to 1,139 patients that needed a CVC for hemodialysis. EC-ECG and a standard chest radiogram controlled the first 100 CVC we placed and in the other 1,039 cases, the control was made by EC-ECG alone. Only in 31 patients (2.7% of all cases), due to arrhythmia, the technique EC-ECG was not utilized. According to our experience, the procedure EC-ECG is an extremely reliable technique, sensitive and specific in 100% of cases, easy for the operator to perform, comfortable for patient. It doesn't need additional time to be performed and eliminates the need of taking a chest radiogram that up to now was considered indispensable in order to verify the position of the catheter tip. In this manner serious complications such as pneumothorax, and haemothorax that can complicate the placement of a CVC can also be avoided. Based on our experience, we now believe that this technique, that today has a large application in nephrology, oncology, clinical nutrition and in various branches of general medicine whenever the placement of a CVC is required, should be considered as a possible new guide line in controlling the placement of a CVC together with a chest X-ray when it is necessary.
Collapse
Affiliation(s)
- P Dionisio
- Department of Nephrology and Dialysis, Ospedale degli Infermi, Biella - Italy
| | | | | | | | | | | |
Collapse
|
50
|
Ang JE, Pal A, Asad YJ, Henley AT, Valenti M, Box G, de Haven Brandon A, Revell VL, Skene DJ, Venturi M, Rueger R, Meresse V, Eccles SA, de Bono JS, Kaye SB, Workman P, Banerji U, Raynaud FI. Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. Mol Cancer Ther 2017; 16:2315-2323. [PMID: 28637716 PMCID: PMC6112418 DOI: 10.1158/1535-7163.mct-16-0881] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Revised: 05/31/2017] [Accepted: 06/06/2017] [Indexed: 01/08/2023]
Abstract
MAPK pathway activation is frequently observed in human malignancies, including melanoma, and is associated with sensitivity to MEK inhibition and changes in cellular metabolism. Using quantitative mass spectrometry-based metabolomics, we identified in preclinical models 21 plasma metabolites including amino acids, propionylcarnitine, phosphatidylcholines, and sphingomyelins that were significantly altered in two B-RAF-mutant melanoma xenografts and that were reversed following a single dose of the potent and selective MEK inhibitor RO4987655. Treatment of non-tumor-bearing animals and mice bearing the PTEN-null U87MG human glioblastoma xenograft elicited plasma changes only in amino acids and propionylcarnitine. In patients with advanced melanoma treated with RO4987655, on-treatment changes of amino acids were observed in patients with disease progression and not in responders. In contrast, changes in phosphatidylcholines and sphingomyelins were observed in responders. Furthermore, pretreatment levels of seven lipids identified in the preclinical screen were statistically significantly able to predict objective responses to RO4987655. The RO4987655 treatment-related changes were greater than baseline physiological variability in nontreated individuals. This study provides evidence of a translational exo-metabolomic plasma readout predictive of clinical efficacy together with pharmacodynamic utility following treatment with a signal transduction inhibitor. Mol Cancer Ther; 16(10); 2315-23. ©2017 AACR.
Collapse
Affiliation(s)
- Joo Ern Ang
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Akos Pal
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom
| | - Yasmin J Asad
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom
| | - Alan T Henley
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom
| | - Melanie Valenti
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom
| | - Gary Box
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom
| | - Alexis de Haven Brandon
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom
| | - Victoria L Revell
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom
| | - Debra J Skene
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom
| | - Miro Venturi
- F. Hoffmann-LaRoche Ltd., Diagnostics Division, DIA Biomarker Group, Basel, Switzerland
| | - Ruediger Rueger
- Roche Pharmaceutical Research and Early Development, Translational Medicine Oncology, Roche Innovation Center Penzberg, Penzberg, Germany
| | - Valerie Meresse
- Roche Pharmaceutical Research and Early Development, Translational Medicine Oncology, Roche Innovation Center Basel, Basel, Switzerland
| | - Suzanne A Eccles
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom
| | - Johann S de Bono
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Stanley B Kaye
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Paul Workman
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom
| | - Udai Banerji
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Florence I Raynaud
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
- Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| |
Collapse
|